LORLATINIB

Brand name:

• Lorviqua®

Pharmaceutical company:

Pfizer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Locally advanced (stage IIIB) or metastatic (stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

PBAC Submission type:

Change to listing (Category 1-2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2021

Related medicines:

--

Submission received for:

July 2021 PBAC meeting

Opportunity for consumer comment:

Open 21/03/2021 and close 26/05/2021 (see PBS Website)

PBAC meeting:

Held on 07/07/2021

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---